Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trFirst-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Practical management of patients with chronic myeloid leukemia.Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phaseBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.The choice of first-line chronic myelogenous leukemia treatment.The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?Chronic myeloid leukemia: mechanisms of resistance and treatment.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureMalignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceEstimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsEUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms.Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction.Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samplesImpact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.How I treat newly diagnosed chronic phase CMLEarly responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
P2860
Q26749324-8E547F83-17E4-4CA8-8D64-48AB1CEB7C71Q26751285-77876559-DCA0-412D-B016-8F76C1BF5409Q30242015-A3918D0C-C9BC-46D4-AE9E-32A08821AAE0Q30370399-D706AB1F-1139-4E09-967E-4E72642D149AQ31033077-FFA8A11F-7628-4C8A-B722-2FC0F5891A01Q33392977-F1FDD78C-E810-48B3-9F01-A57A0BFCDD20Q33402939-99550EC4-C25C-4D98-B30B-A7CEECA5D2B0Q33849146-83872B14-8DE9-4594-9FD9-51B5256A34B2Q33857947-D620762F-28EA-452D-B065-697F49AF7485Q33878636-F08F4B52-83A3-4DC5-81E7-137BE2F4F064Q33926114-F0E441C5-F36A-4E86-8E98-B27A72829951Q34032263-69F15BF0-1090-4C73-A5F7-86E51AD0A665Q34297594-C6FD32E0-42BD-491D-B9C5-41FB83B5F02AQ34417824-8ECC2345-1E1D-48FE-97CD-A86C12DEF50CQ34522789-132F5F4A-6223-4A8C-8F99-68EBB959038DQ34763374-04F5937E-77AC-4AD6-9946-3B8944F2DEB9Q34894883-2865E892-10F5-44C3-947F-BB94CA82FEFBQ35221071-5E3CA29F-7ADC-4D4F-89F6-1F768C0B2CD5Q35548766-FD85943C-5DCA-420C-B272-655C7A5A2814Q35565658-283CDF05-B9A1-43BB-9723-EA653FDA902AQ35595795-E2C111E0-44DC-4099-89CB-C0CAD4F5F7B1Q35596200-25D4E83C-3F3A-4436-825D-32594A22AA5EQ35794105-3FD2D682-1782-4F4F-A211-1CD15260F583Q35794115-3C28BA7B-5F66-4B83-98A4-373C015464DAQ35849204-7F584106-43FE-4732-A4CF-F48C89AF3F88Q35902738-52B33C5E-7EBF-4964-92A9-DC09C6324AF1Q35995232-996EC286-D757-4C71-A1E9-D07B44E1849DQ36094702-E1DCD5CD-0178-4D27-BDA7-5BA66F686E5CQ36104098-F2128478-99D4-4643-85DE-7E012354BE80Q36263943-9054FD8D-9432-41D3-8A25-EB69623D231FQ36450182-24B0D1F7-8C1D-458C-ADFB-99492BF130C9Q36491218-3BC2A66F-1C26-4989-AEBF-7B61F0177716Q36579071-890E54F6-AF68-40BC-A030-6D139F7EC8B9Q36624496-4AEC441C-30D7-4A52-A27A-75DD6719FF86Q36708942-4A39924C-EC2E-4BC0-B7D9-F5FF242F65ADQ36734508-DB8B32BE-1051-436D-89A7-22AD7FBF3675Q36817650-75BCA04E-DD63-4219-8A68-E3FFCE505261Q36920407-47EA3BAC-3DC3-41C3-A6AD-DF228A89632DQ37027767-BC9FE20C-E7D4-41C7-BD29-5BD6607FD7F0Q37095355-C1A7583E-81FC-41D0-9562-B9598F9DAED5
P2860
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@ast
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@en
type
label
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@ast
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@en
prefLabel
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@ast
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@en
P2093
P2860
P50
P356
P1476
Nilotinib as front-line treatm ...... ukemia in early chronic phase.
@en
P2093
Denise Stigliano
Jianqin Shan
P2860
P304
P356
10.1200/JCO.2009.25.4896
P407
P50
P577
2009-12-14T00:00:00Z